Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

References

• Ausserwöger H, Schneider MM, Herling TW, Arosio P, Invernizzi G, Knowles TPJ, Lorenzen N. Non-specificity as the sticky problem in therapeutic antibody development. Nat Rev Chem. 2022;6(12):844–20. Available from https://www.nature.com/articles/s41570-022-00438-x.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang H, Feng N, Li Y, Gu J, Wang Z. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Antib Ther. 2022;6(1):13–29. Available from doi:10.1093/abt/tbac029/6823522.
   PubMedGoogle Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. doi:10.1080/19420862.2018.1553476.
   PubMed Web of Science ®Google Scholar
• Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S, et al. Assessing developability early in the discovery process for novel biologics. MAbs. 2023;15(1):2171248. doi:10.1080/19420862.2023.2171248.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences. 2017;114:944–49. doi:10.1073/pnas.1616408114
   PubMed Web of Science ®Google Scholar
• Lecerf M, Lacombe R, Kanyavuz A, Dimitrov JD. Functional changes of therapeutic antibodies upon exposure to pro-oxidative agents. Antibodies. 2022;11(1):11. Available from doi:10.3390/antib11010011.
   Web of Science ®Google Scholar
• Lecerf M, Kanyavuz A, Rossini S, Dimitrov JD. Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Commun Biol. 2021;4(1):391. Available from http://www.ncbi.nlm.nih.gov/pubmed/33758329.
   PubMed Web of Science ®Google Scholar
• Kraft TE, Richter WF, Emrich T, Knaupp A, Schuster M, Wolfert A, Kettenberger H. Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis. MAbs. 2020;12(1):1683432. Available from http://www.ncbi.nlm.nih.gov/pubmed/31769731.
   PubMed Web of Science ®Google Scholar
• Dietlin-Auril V, Lecerf M, Depinay S, Noé R, Dimitrov JD. Interaction with 2,4-dinitrophenol correlates with polyreactivity, self-binding, and stability of clinical-stage therapeutic antibodies. Mol Immunol. 2021;140:233–39. Available from https://linkinghub.elsevier.com/retrieve/pii/S0161589021003096.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Geoghegan JC, Feldman J, Jain T, Kauke M, Le D, Zhao J, Wittrup KD. Chaperone proteins as single component reagents to assess antibody nonspecificity. MAbs. 2017;9(7):1036–40. Available from http://www.ncbi.nlm.nih.gov/pubmed/28745541.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Wu L, Desai AA, Tessier PM. Highly sensitive detection of antibody nonspecific interactions using flow cytometry. MAbs. 2021;13(1):1951426. Available from http://www.ncbi.nlm.nih.gov/pubmed/34313552.
   PubMed Web of Science ®Google Scholar
• Willis LF, Kumar A, Jain T, Caffry I, Xu Y, Radford SE, Kapur N, Vásquez M, Brockwell DJ. The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies. Eng Rep. 2020;2(5). Available from. doi:10.1002/eng2.12147.
   PubMedGoogle Scholar
• Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467(7315):591–95. doi:10.1038/nature09385.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Lai P-K, Fernando A, Cloutier TK, Kingsbury JS, Gokarn Y, Halloran KT, Calero-Rubio C, Trout BL. Machine learning feature selection for predicting high concentration therapeutic antibody aggregation. J Pharm Sci. 2021;110(4):1583–91. Available from https://linkinghub.elsevier.com/retrieve/pii/S0022354920307930.
   PubMed Web of Science ®Google Scholar
• Grinshpun B, Thorsteinson N, Pereira JN, Rippmann F, Nannemann D, Sood VD, Fomekong Nanfack Y. Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies. MAbs. 2021;13(1). Available from. doi:10.1080/19420862.2021.1932230.
   PubMed Web of Science ®Google Scholar
• Thorsteinson N, Gunn JR, Kelly K, Long W, Labute P. Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics. MAbs. 2021;13(1):1981805. Available from http://www.ncbi.nlm.nih.gov/pubmed/34632944.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116(10):4025–30. Available from http://www.ncbi.nlm.nih.gov/pubmed/30765520.
   PubMed Web of Science ®Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proceedings of the National Academy of Sciences. 2021;118. doi:10.1073/pnas.2020577118
   Web of Science ®Google Scholar
• Zhang Y, Wu L, Gupta P, Desai AA, Smith MD, Rabia LA, Ludwig SD, Tessier PM. Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity. Mol Pharm. 2020;17(7):2555–69. Available from http://www.ncbi.nlm.nih.gov/pubmed/32453957.
   PubMedGoogle Scholar
• Shehata L, Maurer DP, Wec AZ, Lilov A, Champney E, Sun T, Archambault K, Burnina I, Lynaugh H, Zhi X, et al. Affinity maturation enhances antibody specificity but compromises conformational stability. Cell Rep. 2019;28(13):3300–8.e4. doi:10.1016/j.celrep.2019.08.056.
   PubMed Web of Science ®Google Scholar
• Hebditch M, Warwicker J. Charge and hydrophobicity are key features in sequence-trained machine learning models for predicting the biophysical properties of clinical-stage antibodies. PeerJ. 2019;7:e8199. Available from https://peerj.com/articles/8199.
   PubMed Web of Science ®Google Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. MAbs. 2020;12(1): Available from. doi: 10.1080/19420862.2020.1743053.
   Web of Science ®Google Scholar
• Negron C, Fang J, McPherson MJ, Stine WB, McCluskey AJ. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment. MAbs. 2022;14(1). Available from. doi:10.1080/19420862.2022.2080628.
   PubMed Web of Science ®Google Scholar
• Waibl F, Fernández-Quintero ML, Kamenik AS, Kraml J, Hofer F, Kettenberger H, Georges G, Liedl KR. Conformational ensembles of antibodies determine their Hydrophobicity. Biophys J. 2021;120(1):143–57. doi:10.1016/j.bpj.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Waibl F, Fernández-Quintero ML, Wedl FS, Kettenberger H, Georges G, Liedl KR. Comparison of hydrophobicity scales for predicting biophysical properties of antibodies. Front Mol Biosci. 2022;9. 10.3389/fmolb.2022.960194
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xie S, Yang Y, Jiang L, Liu S, Li W, Abagna HB, Ning L, Huang J. SSH2.0: a better tool for predicting the Hydrophobic interaction risk of monoclonal Antibody. Front Genet. 2022;13. doi:10.3389/fgene.2022.842127.
   Web of Science ®Google Scholar
• Jain T, Boland T, Lilov A, Burnina I, Brown M, Xu Y, Vásquez M, Valencia A. Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning. Bioinformatics. 2017;33(23):1–9. Available from http://academic.oup.com/bioinformatics/article/doi/10.1093/bioinformatics/btx519/4083264/Prediction-of-delayed-retention-of-antibodies-in.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Le D, Zhao J, Wittrup KD. Reduction of nonspecificity motifs in synthetic antibody libraries. J Mol Biol. 2018;430(1):119–30. doi:10.1016/j.jmb.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Rabia LA, Zhang Y, Ludwig SD, Julian MC, Tessier PM. Net charge of antibody complementarity-determining regions is a key predictor of specificity. Protein Eng Des Sel. 2019:1–10. Available from. doi:10.1093/protein/gzz002/5321218.
   PubMed Web of Science ®Google Scholar
• Gupta P, Makowski EK, Kumar S, Zhang Y, Scheer JM, Tessier PM. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties. Mol Pharm. 2022;19(3):775–87. doi:10.1021/acs.molpharmaceut.1c00373.
   PubMedGoogle Scholar
• Leem J, Dunbar J, Georges G, Shi J, CM D. ABodyBuilder: automated antibody structure prediction with data–driven accuracy estimation. MAbs. 2016;8(7):1259–68. doi:10.1080/19420862.2016.1205773.
   PubMed Web of Science ®Google Scholar
• Labute P. Protonate3d: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins Struct Funct Bioinf. 2009;75(1):187–205. doi:10.1002/prot.22234.
   PubMed Web of Science ®Google Scholar
• Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions. J Chem Theory Comput. 2011;7(2):525–37. doi:10.1021/ct100578z.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vasquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70. Available from. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Fekete S, Veuthey J-L, Beck A, Guillarme D. Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products. J Pharm Biomed Anal. 2016;130:3–18. Available from http://www.ncbi.nlm.nih.gov/pubmed/27084526.
   PubMed Web of Science ®Google Scholar
• Hu S, Datta-Mannan A, D’Argenio DZ. Physiologically based modeling to predict monoclonal antibody pharmacokinetics in humans from in vitro physiochemical properties. MAbs. 2022;14(1):2056944. Available from http://www.ncbi.nlm.nih.gov/pubmed/35491902.
   PubMed Web of Science ®Google Scholar
• Chung S, Nguyen V, Lin YL, Lafrance-Vanasse J, Scales SJ, Lin K, Deng R, Williams K, Sperinde G, Li JJ, et al. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs. 2019;11(5):942–55. Available from. doi:10.1080/19420862.2019.1605270.
   PubMed Web of Science ®Google Scholar
• Warne NW. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur J Pharm Biopharm. 2011;78(2):208–12. Available from https://linkinghub.elsevier.com/retrieve/pii/S0939641111000889.
   PubMed Web of Science ®Google Scholar
• Yadav S, Sreedhara A, Kanai S, Liu J, Lien S, Lowman H, Kalonia DS, Shire SJ. Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res. 2011 [[cited 2013 Nov 5]];28(7):1750–64. doi:10.1007/s11095-011-0410-0.
   Google Scholar
• Hotzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012 [cited 2013 Feb 28]; 4:753–60. Available from: http://www.landesbioscience.com/journals/mabs/article/22189/
   PubMed Web of Science ®Google Scholar
• Hu S, Datta-Mannan A, Argenio DZD, Hu S. Physiologically based modeling to predict monoclonal antibody pharmacokinetics in humans from in vitro physiochemical properties. MAbs. 2022;14(1). Available from. doi:10.1080/19420862.2022.2056944.
   Web of Science ®Google Scholar
• Starr CG, Makowski EK, Wu L, Berg B, Kingsbury JS, Gokarn YR, Tessier PM. Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties. Mol Pharm. 2021;18(7):2744–53. Available from doi:10.1021/acs.molpharmaceut.1c00280.
   PubMedGoogle Scholar
• Chai Q, Shih J, Weldon C, Phan S, Jones BE. Development of a high-throughput solubility screening assay for use in antibody discovery. MAbs. 2019;11(4):747–56. Available from doi:https://doi.org/10.1080/19420862.2019.1589851.
   PubMed Web of Science ®Google Scholar
• Phan S, Walmer A, Shaw EW, Chai Q. High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy. MAbs. 2022;14(1). Available from. doi:10.1080/19420862.2022.2094750.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. 2020. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 6(32). doi:10.1126/sciadv.abb0372.
   PubMed Web of Science ®Google Scholar
• Wu S-J, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel. 2010;23(8):643–51. Available from. doi:10.1093/protein/gzq037.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. 2016. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 6(1). doi:10.1038/srep38644.
   Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs. 2015;7(3):483–93. doi:10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010;114(19):6614–24. Available from http://www.ncbi.nlm.nih.gov/pubmed/20411962.
   PubMed Web of Science ®Google Scholar
• Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. 2020. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 12(1). doi:10.1080/19420862.2020.1829335.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences. 2015; 112:5997–6002. Available from: 10.1073/pnas.1408766112
   PubMed Web of Science ®Google Scholar
• Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9(4):791–802. Available from http://pubs.acs.org/doi/abs/10.1021/mp200566k.
   PubMed Web of Science ®Google Scholar
• Han X, Shih J, Lin Y, Chai Q, Cramer SM. Development of QSAR models for in silico screening of antibody solubility. MAbs. 2022;14(1). Available from. doi:https://doi.org/10.1080/19420862.2022.2062807.
   Web of Science ®Google Scholar
• Sormanni P, Vendruscolo M. Protein solubility predictions using the camsol method in the study of protein homeostasis. Cold Spring Harb Perspect Biol. 2019;11(12):11. doi:10.1101/cshperspect.a033845.
   Web of Science ®Google Scholar
• Feng J, Jiang M, Shih J, Chai Q. Antibody apparent solubility prediction from sequence by transfer learning. iSci. 2022;25(10):105173. Available from https://linkinghub.elsevier.com/retrieve/pii/S2589004222014456.
   PubMed Web of Science ®Google Scholar
• Lai P-K, Fernando A, Cloutier TK, Gokarn Y, Zhang J, Schwenger W, Chari R, Calero-Rubio C, Trout BL. Machine learning applied to determine the molecular descriptors responsible for the viscosity behavior of concentrated therapeutic antibodies. Mol Pharm. 2021;18(3):1167–75. Available from doi:10.1021/acs.molpharmaceut.0c01073.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proceedings of the National Academy of Sciences. 2014; 111:18601–06. Available from: 10.1073/pnas.1421779112
   PubMed Web of Science ®Google Scholar
• Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs. 2016;8(1):43–48. Available from doi:10.1080/19420862.2015.1099773.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Singh SK, Li L, Broulidakis MP, Kumar S. In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors. Pharm Res. 2018;35(10). doi:10.1007/s11095-018-2466-6.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. MAbs. 2017;9(3):476–89. Available from doi:10.1080/19420862.2017.1285479.
   PubMed Web of Science ®Google Scholar
• Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012 [[cited 2013 Jan 29]];101(1):102–15. doi:10.1002/jps.22758.
   PubMed Web of Science ®Google Scholar
• van Durme J, de Baets G, van der Kant R, Ramakers M, Ganesan A, Wilkinson H, Gallardo R, Rousseau F, Schymkowitz J. Solubis: a webserver to reduce protein aggregation through mutation. Protein Eng Des Sel. 2016;29(8):285–89. doi:10.1093/protein/gzw019.
   PubMed Web of Science ®Google Scholar
• Heads JT, Kelm S, Tyson K, Lawson ADG. A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers. MAbs. 2022;14(1). doi:10.1080/19420862.2022.2138092.
   PubMed Web of Science ®Google Scholar
• Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Mølhøj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of Asparagine and Aspartate degradation sites in antibody variable regions. PLoS One. 2014;9(6):e100736. Available from. doi:10.1371/journal.pone.0100736.
   PubMed Web of Science ®Google Scholar
• Yang R, Jain T, Lynaugh H, Nobrega RP, Lu X, Boland T, Burnina I, Sun T, Caffry I, Brown M, et al. Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies. MAbs. 2017;9(4):646–53. doi:10.1080/19420862.2017.1290753.
   PubMed Web of Science ®Google Scholar
• Delmar JA, Buehler E, Chetty AK, Das A, Quesada GM, Wang J, Chen X. Machine learning prediction of methionine and tryptophan photooxidation susceptibility. Mol Ther Methods Clin Dev. 2021;21:466–77. doi:10.1016/j.omtm.2021.03.023.
   PubMed Web of Science ®Google Scholar
• Sankar K, Hoi KH, Yin Y, Ramachandran P, Andersen N, Hilderbrand A, McDonald P, Spiess C, Zhang Q. Prediction of methionine oxidation risk in monoclonal antibodies using a machine learning method. MAbs. 2018;10(8):1281–90. doi:10.1080/19420862.2018.1518887.
   PubMed Web of Science ®Google Scholar
• Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs2022. 2022;14(1):14. doi:10.1080/19420862.2021.2020082.
   Web of Science ®Google Scholar
• Bujotzek A, Fuchs A, Qu C, Benz JO, Klostermann S, Antes I, Georges G. MoFvAb: modeling the Fv region of antibodies. MAbs. 2015;7(5):838–52. doi:10.1080/19420862.2015.1068492.
   PubMed Web of Science ®Google Scholar
• Ruffolo JA, Chu L-S, Pooja Mahajan S, Gray JJ. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. bioRxiv. 2022;1 Available from. doi:10.1101/2022.04.20.488972.
   Google Scholar
• Abanades B, Georges G, Bujotzek A, Deane CM, Xu J. Ablooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics. 2022;38(7):1877–80. doi:10.1093/bioinformatics/btac016.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–89. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM. Thera-SAbDab: the therapeutic structural antibody database. Nucleic Acids Res. 2020;48(D1):D383–8. doi:10.1093/nar/gkz827.
   PubMed Web of Science ®Google Scholar